Filtered By:
Source: Diabetes Care
Condition: Diabetes

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 76 results found since Jan 2013.

Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
CONCLUSIONS The presence of major ECG abnormalities is associated with an increased risk of CVD in patients with type 1 diabetes. This suggests a potential role for ECG screening in patients with type 1 diabetes to identify individuals at risk for CVD.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Soliman, E. Z.; Backlund, J.-Y. C.; Bebu, I.; Orchard, T. J.; Zinman, B.; Lachin, J. M.; the DCCT/EDIC Research Group Tags: Cardiovascular and Metabolic Risk Source Type: research

Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators
CONCLUSIONS A large initial HbA1c reduction and achievement of low HbA1c levels within 6 months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Svensson, E.; Baggesen, L. M.; Johnsen, S. P.; Pedersen, L.; Norrelund, H.; Buhl, E. S.; Haase, C. L.; Thomsen, R. W. Tags: Cardiovascular and Metabolic Risk Source Type: research

Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry
CONCLUSIONS The presence of diabetes markedly increases the risk of 1-year adverse clinical outcomes in outpatients with CHF independent of multiple common risk factors. More effective and personalized treatment for diabetes should be considered in this particularly high-risk patient population.
Source: Diabetes Care - April 20, 2017 Category: Endocrinology Authors: Dauriz, M.; Targher, G.; Laroche, C.; Temporelli, P. L.; Ferrari, R.; Anker, S.; Coats, A.; Filippatos, G.; Crespo-Leiro, M.; Mebazaa, A.; Piepoli, M. F.; Maggioni, A. P.; Tavazzi, L.; for the ESC-HFA Heart Failure Long-Term Registry Tags: Cardiovascular and Metabolic Risk Source Type: research

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
CONCLUSIONS Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
Source: Diabetes Care - March 20, 2017 Category: Endocrinology Authors: Bethel, M. A.; Engel, S. S.; Green, J. B.; Huang, Z.; Josse, R. G.; Kaufman, K. D.; Standl, E.; Suryawanshi, S.; Van de Werf, F.; McGuire, D. K.; Peterson, E. D.; Holman, R. R.; for the TECOS Study Group Tags: Emerging Science and Concepts for Management of Diabetes and Aging Source Type: research

Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
CONCLUSIONS Adults with both high TG and low HDL-C, particularly those with diabetes, have increased risks of incident CHD and stroke. In particular, those with an LDL-C level ≥130 mg/dL may have an increased risk of incident stroke.
Source: Diabetes Care - March 20, 2017 Category: Endocrinology Authors: Lee, J. S.; Chang, P.-Y.; Zhang, Y.; Kizer, J. R.; Best, L. G.; Howard, B. V. Tags: Epidemiology/Health Services Research Source Type: research

Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes
CONCLUSIONS The absolute risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception is low. Highly effective, intrauterine and subdermal contraceptives are excellent options for women with diabetes who hope to avoid the teratogenic effects of hyperglycemia by carefully planning their pregnancies.
Source: Diabetes Care - January 19, 2017 Category: Endocrinology Authors: OBrien, S. H.; Koch, T.; Vesely, S. K.; Schwarz, E. B. Tags: Epidemiology/Health Services Research Source Type: research

Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes
CONCLUSIONS In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem cells predicts adverse cardiovascular outcomes up to 6 years later and improves risk stratification.
Source: Diabetes Care - December 19, 2016 Category: Endocrinology Authors: Fadini, G. P.; Rigato, M.; Cappellari, R.; Bonora, B. M.; Avogaro, A. Tags: Cardiovascular and Metabolic Risk Source Type: research

Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes
CONCLUSIONS Absent dorsalis pedis and/or posterior tibial pulses are independent predictors of major vascular outcomes in patients with type 2 diabetes. These simple clinical indicators should be used to improve risk stratification and treatment of these patients.
Source: Diabetes Care - November 21, 2016 Category: Endocrinology Authors: Mohammedi, K.; Woodward, M.; Zoungas, S.; Li, Q.; Harrap, S.; Patel, A.; Marre, M.; Chalmers, J.; on behalf of the ADVANCE Collaborative Group Tags: Pathophysiology/Complications Source Type: research

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
CONCLUSIONS Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.
Source: Diabetes Care - September 21, 2016 Category: Endocrinology Authors: Inzucchi, S. E.; Viscoli, C. M.; Young, L. H.; Furie, K. L.; Gorman, M.; Lovejoy, A. M.; Dagogo-Jack, S.; Ismail-Beigi, F.; Korytkowski, M. T.; Pratley, R. E.; Schwartz, G. G.; Kernan, W. N.; for the IRIS Trial Investigators Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
CONCLUSIONS In patients with type 2 diabetes and a recent ACS, the risk of CV death was higher after a postrandomization, nonfatal CV event, particularly heart failure, compared with those who did not experience a CV event. The risk of CV death was similar between alogliptin and placebo.
Source: Diabetes Care - June 20, 2016 Category: Endocrinology Authors: White, W. B.; Kupfer, S.; Zannad, F.; Mehta, C. R.; Wilson, C. A.; Lei, L.; Bakris, G. L.; Nissen, S. E.; Cushman, W. C.; Heller, S. R.; Bergenstal, R. M.; Fleck, P. R.; Cannon, C. P.; for the EXAMINE Investigators Tags: Cardiovascular and Metabolic Risk Source Type: research

Prognostic Value of Coronary Computed Tomography Angiography in Patients With Diabetes: A Meta-analysis
CONCLUSIONS CTA in patients with diabetes allows for safely ruling out future events, and the detection of CAD could allow for the identification of high-risk patients in whom aggressive risk factor modification, medical surveillance, or elective revascularization could potentially improve survival.
Source: Diabetes Care - June 20, 2016 Category: Endocrinology Authors: Celeng, C.; Maurovich-Horvat, P.; Ghoshhajra, B. B.; Merkely, B.; Leiner, T.; Takx, R. A. P. Tags: Meta-analysis Source Type: research

Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes
CONCLUSIONS This observational study shows that LLT is associated with 22–44% reduction in the risk of CVD and cardiovascular death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes.
Source: Diabetes Care - May 23, 2016 Category: Endocrinology Authors: Hero, C.; Rawshani, A.; Svensson, A.-M.; Franzen, S.; Eliasson, B.; Eeg-Olofsson, K.; Gudbjörnsdottir, S. Tags: Epidemiology/Health Services Research Source Type: research

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
CONCLUSIONS Abnormal levels of NTproBNP and troponin T may help to distinguish individuals with high diabetes risk from those with low diabetes risk, providing incremental risk prediction beyond commonly used markers of risk.
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Gori, M.; Gupta, D. K.; Claggett, B.; Selvin, E.; Folsom, A. R.; Matsushita, K.; Bello, N. A.; Cheng, S.; Shah, A.; Skali, H.; Vardeny, O.; Ni, H.; Ballantyne, C. M.; Astor, B. C.; Klein, B. E.; Aguilar, D.; Solomon, S. D. Tags: Cardiovascular Disease and Diabetes Source Type: research

Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
CONCLUSIONS Intensive diabetes therapy during the DCCT (6.5 years) has long-term beneficial effects on the incidence of cardiovascular disease in type 1 diabetes that persist for up to 30 years.
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Tags: Cardiovascular Disease and Diabetes Source Type: research

Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes
CONCLUSIONS In high-risk people with type 2 diabetes monitored for 9 years, a mean of 3.7 years of intensive glycemic control had a neutral effect on death and nonfatal cardiovascular events but increased cardiovascular-related death.
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: The ACCORD Study Group Tags: Cardiovascular Disease and Diabetes Source Type: research